Increased Immunogenicity of Full-Length Protein Antigens through Sortase-Mediated Coupling on the PapMV Vaccine Platform.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

16 citing papers in PubMed.

1. Engineering a Modular PapMV Nanoparticle Vaccine: Comparative Efficacy of a Covalent and a Non-Covalent N-Antigen Vaccine Against Emerging SARS-CoV-2 Variants.Vaccines · 2026
   Article
2. Presentation of hemagglutinin on adjuvant-bearing self-assembling peptide nanofibers increases heterologous responses against influenza.Acta biomaterialia · 2026
   Article
3. Chemical and biological conjugation strategies for the development of multivalent protein vaccine nanoparticles.Biopolymers · 2023
   Review
4. Protein-Based Adjuvants for Vaccines as Immunomodulators of the Innate and Adaptive Immune Response: Current Knowledge, Challenges, and Future Opportunities.Pharmaceutics · 2022
   Review
5. A nanoparticle-based COVID-19 vaccine candidate elicits broad neutralizing antibodies and protects against SARS-CoV-2 infection.Nanomedicine : nanotechnology, biology, and medicine · 2022
   Article
6. Biological Nanoparticles in Vaccine Development.Frontiers in bioengineering and biotechnology · 2022
   Review
7. Plant-derived VLP: a worthy platform to produce vaccine against SARS-CoV-2.Biotechnology letters · 2022
   Review
8. Combating Human Viral Diseases: Will Plant-Based Vaccines Be the Answer?Vaccines · 2021
   Review
9. Advancements in protein nanoparticle vaccine platforms to combat infectious disease.Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology · 2021
   Review
10. Modulation of Antigen Display on PapMV Nanoparticles Influences Its Immunogenicity.Vaccines · 2021
    Article
11. Convenient Auto-Processing Vector Based on Bamboo Mosaic Virus for Presentation of Antigens Through Enzymatic Coupling.Frontiers in immunology · 2021
    Article
12. Rapid High-Yield Production of Functional SARS-CoV-2 Receptor Binding Domain by Viral and Non-Viral Transient Expression for Pre-Clinical Evaluation.Vaccines · 2020
    Article
13. A Randomized Controlled Study to Evaluate the Safety and Reactogenicity of a Novel rVLP-Based Plant Virus Nanoparticle Adjuvant Combined with Seasonal Trivalent Influenza Vaccine Following Single Immunization in Healthy Adults 18-50 Years of Age.Vaccines · 2020
    Article
14. Better Adjuvants for Better Vaccines: Progress in Adjuvant Delivery Systems, Modifications, and Adjuvant-Antigen Codelivery.Vaccines · 2020
    Review
15. Recent Advances in the Use of Plant Virus-Like Particles as Vaccines.Viruses · 2020
    Review
16. Nanoparticles in influenza subunit vaccine development: Immunogenicity enhancement.Influenza and other respiratory viruses · 2020
    Review

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

Authors and funding

8 authors.

Funding

Abstract

PubMed holds no abstract for this paper.

Indexed as